Marbiopharm

History

2024: The court arrested the property of the drug manufacturer "Marbiopharm"

On June 4, 2024, the Moscow Arbitration Court partially satisfied the application of the Penza Region Prosecutor's Office and arrested the movable and immovable property of Marbiofarm JSC. The decision was made in the framework of the bankruptcy case of JSC MPPDK Biotek, which owns 97.77% of Marbiopharma shares.

The court ruling provides that the arrest does not affect funds intended for the payment of salaries, payment of taxes and fees, payment of utilities and settlement with suppliers of medicines and medical devices. Also, the drugs themselves are not subject to arrest.

𝓲

Unsplash

In January 2024, the Oktyabrsky District Court of Penza, at the suit of the Prosecutor General, recovered 8.2 billion rubles from the former governor of the Penza region, Ivan Belozertsev, and other defendants in the case, including the companies of the Biotek group and their beneficiaries. This recovery could lead to the re-registration of Marbiopharma's property to third parties, which necessitated interim measures to prevent significant damage to the Russian Federation.

The prosecutor's office also asked the court to prohibit Marbiofarm from taking actions to alienate assets, reduce their value, stop production processes, pay dividends, distribute profits and losses, pay remuneration to managers and open new bank accounts. The court refused to satisfy this part of the application.

The appeal to the state income of funds in the amount of more than 8 billion rubles, subject to collection in solidarity, including from the debtor, may cause the re-registration of Marbiopharm JSC of its property to third parties, which will lead to the impossibility of executing the judicial act and, as a result, will bring significant damage to the Russian Federation, the court ruling says.[1]

2015

• commissioning of the finished product warehouse.
• commissioning of the solid drug production department.

2014

Commissioning of the Liquid Drug Packaging and Packaging Area.

2010

Commissioning of the packaging area for tablets, capsules and other dosage forms.

2005

In 2005 the organization joined the Biotek group of companies and became known as Marbiopharm OJSC.

2004

In 2004, the organization joined the Pharmstandard group of companies and became known as OJSC Pharmstandard-Marbiopharm..

1992

In 1992 the enterprise (organization) acquired the status of an open joint-stock company, and in 1997. became part of the international pharmaceutical corporation ICN Pharmacuticals.Inc. and became known as JSC "ASI En Marbiopharm."

1996

Commissioning of the 2nd section of the HFS production workshop.

1985

Reconstruction of the lipoic acid synthesis shop.

1978

Commissioning of sorbitol production using continuous technology with a capacity of 5000 tons per year.

1976

Commissioning of the sorbitol and sorbose production shop for related enterprises of the Ministry of Medical Industry producing ascorbic acid.

1973

Reconstruction of the ascorbic acid synthesis workshop, increase in capacity to 200 tons per year.

1971

Commissioning of lipoic acid and lipamide synthesis shop.

1963

Commissioning of a workshop for the production of finished medicines.

1954

Commissioning of the ascorbic acid synthesis workshop with a capacity of 40 tons per year.

1950

Commissioning of the plant vitamins workshop.

1942: Creation of the Company

The first production took place in November 1942, which is considered the date of foundation of the plant.

Notes